William Wood
Analyst
B. Riley Securities
Equibles does not estimate personal net worth.
About William Wood
William Wood is recorded as Analyst at B. Riley Securities. William Wood has spoken on 14 earnings calls across 6 companies, most recently for Viking Therapeutics, Inc. on October 28, 2026. Those appearances were for Viking Therapeutics, Inc. (VKTX), Altimmune, Inc. (ALT), Tg Therapeutics, Inc. (TGTX), Trevi Therapeutics, Inc. (TRVI), Madrigal Pharmaceuticals, Inc. (MDGL) and 1 other company. The companies whose calls William Wood spoke on are classified in the Healthcare sector.
William Wood on recent calls
“Maybe just thinking about the Vanquish extension study, that looks to get underway in first quarter of 2027. This will obviously read out before part two maintenance trial readout.”
“And if you are thinking about sort of, you know, keeping them separate since just given the time, how much would you, you know, could we read through from Ocean 2 to Ocean 1, just given the different lengths of time, 12 versus 24 weeks?”
“When we're thinking about sort of the second half in the year-end guidance, your fourth quarter or your $1 billion exit runway implies a fourth quarter of around $250 million, which leaves third quarter relatively flat.”
“I'm just, I want to verify that in the top line readout for your maintenance trial coming up, you had mentioned the importance of those dose curves, and I just wanted to make sure that we will get the dose curves for both the induction and the maintenance setting.”
Affiliation history
-
B. Riley Securities
Analyst
Source not stated
Current
Company network
Altimmune, Inc.
ALT
Biotechnology · Healthcare
3 appearances
Latest appearance 2026-08-12
View calls and events
Fractyl Health, Inc.
GUTS
Biotechnology · Healthcare
1 appearance
Latest appearance 2025-08-12
View calls and events